Slide 1: Results as of December 31, 2024
Results as of December 31, 2024
Slide 2: Safe Harbor and Regulation G Statement
Safe Harbor and Regulation G Statement This presentation contains information about Chemed’s EBITDA, Adjusted EBITDA, EBIT, Adjusted EBIT, Adjusted Net Income and Adjusted Diluted EPS, which are not measures derived in accordance with GAAP and which exclude components that are important to understan
Slide 3: Cumulative Results Since the VITAS Acquisition
Cumulative Results Since the VITAS Acquisition For the years ended December 31, 2003 through 2024 (1) (2) (3) CAGR One Three Twenty-One Year Year Year (a) Chemed (1) Service revenues and sales 7.4% 4.4% 11.2% (2) Adj. net income 13.8% 4.5% 19.8% (3) Adj. diluted EPS from continuing operations 13.9%
Slide 4: Chemed – Purchase of Capital Stock
Chemed – Purchase of Capital Stock For the Period January 1, 2007, through December 31, 2024 ($000) (1) (2) (3) (4) Total Free Shares Returned to Cash Flow Repurchased Dividends Shareholders Generated (1) (1) Activity in 2007 $ 127,881 $ 5,888 $ 133,769 $ 72,944 (2) Activity in 2008 67,126 5,543 72,
Slide 5: Adj. EPS and Stock Price History
(1) (2) Adj. EPS and Stock Price History Chemed has delivered strong and consistent EPS to Adj. Diluted stockholders since 2003, 21.3% 21-year CAGR Adj. Stock EPS Price $24.00 $650 $23.00 $625 $22.00 $600 $21.00 $575 $20.00 $550 $19.00 $525 $18.00 $500 $17.00 $475 $16.00 $450 $425 $15.00 $400 $14.00
Slide 6: Chemed – Consolidated Summary of Operations
Chemed – Consolidated Summary of Operations For the years ended December 31, 2003 through 2024 (in thousands, except per share data) (1) (2) (3) (5) (7) (8) (9) (10) (11) (12) (13) (14) (15) Average Annual 2003 2011 2013 2015 2017 2018 2019 2020 2021 2022 2023 2024 Inc./(Dec.) (1) Service Revenues a
Slide 7: Chemed - Results from Continuing Operations
Chemed - Results from Continuing Operations (in thousands, except per share data) (1) (2) (3) Full-Year Results Fav/(Unfav) 2023 2024 % Growth (1) Service Revenues and Sales $2,264,417 $2,431,287 7.4% (2) Adj. EBITDA (a) 451,897 503,002 11.3% (3) Adj. EBITDA Margin (a) 20.0% 20.7% 0.7 pts. (4) Adj.
Slide 8: Chemed Corporation Revenue
Chemed Corporation Revenue 2024 2023 Roto-Rooter Roto-Rooter 37% 42% 63% 58% VITAS VITAS Chemed Chemed Roto-Rooter Central Support Chemed Roto-Rooter Central Support Chemed Central Support 0.8% Central Support 1.1% Adjusted EBITDA Adjusted EBITDA 9.6% (a) 10.1% (a) Roto-Rooter 20.7% 20.0% COS Roto-R
Slide 9: Plumbing & Water Cleanup
PLUMBING & WATER CLEANUP
Slide 10: Roto-Rooter Company Overview
Roto-Rooter Company Overview ◆ Largest provider of plumbing and drain cleaning services in North America Provides plumbing services to approximately 90% of the United States and 30% of the Canadian population ◆ Provides plumbing and drain cleaning services in 123 company-owned territories and 348
Slide 11: Chemed Growth Strategy – Roto-Rooter
Chemed Growth Strategy – Roto-Rooter ◆ Continue to increase efficiency ◆ Acquire franchisee territories at reasonable valuations $75 - $100 million in franchise street sales in desirable markets Purchase at 6-8 times Proforma Adjusted EBITDA Minimal capital expenditure ◆ Focus on earnings and
Slide 12: Roto-Rooter – Gross Revenue Analysis
Roto-Rooter – Gross Revenue Analysis ($000) $368.2 $392.1 $427.8 $453.6 $518.5 $592.0 $663.6 $750.7 $882.5 $938.0 $957.1 $909.5 $1,000 $950 $900 $850 $800 $750 $700 $650 Millions $600 $550 $500 $450 $400 $350 $300 $250 $200 $150 $100 $50 $0 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Slide 13: Roto-Rooter – Summary of Operations 2004-2012
Roto-Rooter – Summary of Operations 2004 through 2012 (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) (9) 2004 2005 2006 2007 2008 2009 2010 2011 2012 (1) Service Revenues $ 276,611 $ 297,337 $ 319,495 $ 344,632 $ 340,496 $ 335,893 $ 354,735 $ 369,698 $ 363,006 and Sales (a) (2) E
Slide 14: Roto-Rooter – Summary of Operations 2013-2024
Roto-Rooter – Summary of Operations 2013 through 2024 (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) Average Annual Inc./(Dec.) 2013 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2004-2024 (1) Service Revenues $ 368,216 $ 427,837 $ 453,564 $ 518,464 $ 585,0
Slide 15: Roto-Rooter – Results from Continuing Operations
Roto-Rooter – Results from Continuing Operations ($000) (1) (2) (3) Full-Year Results Fav/(Unfav) 2023 2024 % Growth (1) Service Revenues and Sales $ 949,352 $ 900,309 (5.2%) (2) Net Income (GAAP) 188,241 160,046 (15.0%) (3) Adj. EBITDA (a) (b) 269,570 237,087 (12.0%) (4) Adj. EBITDA Margin (a) (b)
Slide 16: Future of Roto-Rooter
Future of Roto-Rooter ◆ Continue to Consolidate Franchises Purchase at reasonable multiples Avoid over-paying for current acquisitions Inflates expectations/demands of remaining franchisees ◆ Utilize Cash Flow for: Purchase of franchises Acquisition of hospices Share buy-back, increased d
Slide 17: VITAS Healthcare
_ VITAS Healthcare
Slide 18: VITAS Healthcare Company Overview
VITAS Healthcare Company Overview ◆ One of the largest providers of hospice services for patients with severe, life-limiting illnesses with approximately 7-8% of the U.S. market share ◆ Operates a comprehensive range of hospice services through 55 operating programs in 16 states and the District of
Slide 19: VITAS – Analysis of Revenue
VITAS – Analysis of Revenue Days of Care - 2024 Revenues - 2024 1.4% 1.2% 8% 6% 97.4% 86% Revenue and Expenses - 2024 Adjusted EBITDA - 2024 Field Patient Hospice Program 74.9% Care Direct 51.9% 14.2% Income 6.5% 6.5% Taxes 21.7% 19.9% 4.4% Hospice Central Net Depreciation - Program Central Amortiza
Slide 20: VITAS – Operations as a Percent of Revenue
VITAS – Operations as a Percent of Revenue 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 2004 2006 2008 2010 2012 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 Revenue Cost of Field Based Patient Care as a % of Sales Central Support Overhead as a % of Revenue Adj. Net Income as a % of Sales (1) 20
Slide 21: VITAS – Locations
VITAS – Locations 21 Chemed Corporation
Slide 22: VITAS 2024 Discharge Rate – Total (Median)
VITAS 2024 Discharge Rate – Total Median 22 Chemed Corporation
Slide 23: VITAS 2024 Discharge Rate – Total (After Days)
VITAS 2024 Discharge Rate – Total After 180 Days 23 Chemed Corporation
Slide 24: VITAS Admissions by Diagnosis - 2024
VITAS Admissions by Diagnosis - 2024 Cancer 13.8% 25.3% Cardio 7.6% 9.9% 15.6% Cerebro Respiratory 27.8% Neurological All Other 24 Chemed Corporation
Slide 25: VITAS 2024 Discharge Rate – All Diagnosis
VITAS 2024 Discharge Rate – All Diagnosis Population: 64,618 100% 90% 80% Cancer 26.0% of Total (MLOS 12) 70% Cardio 15.6% of Total (MLOS 25) Cerebro 27.2% of Total (MLOS 42) 60% Gastro 00.2% of Total (MLOS 5) HIV 00.2% of Total (MLOS 6) 50% Ill Def 00.0% of Total (MLOS 0) Infect 00.2% of Total (MLO
Slide 26: Analysis of VITAS Discharges 2004-2024
Analysis of VITAS Discharges 2004-2024 Total Discharges Total Live Discharges 26 Chemed Corporation
Slide 27: VITAS Analysis of Gross Revenue By Level of Care
VITAS Analysis of Gross Revenue By Level of Care 2003 through 2024 ($000) 27 Chemed Corporation
Slide 28: VITAS Analysis of Average Daily Census (ADC)
VITAS Analysis of Average Daily Census (ADC) 2003 through 2024 28 Chemed Corporation
Slide 29: VITAS Direct Gross Profit Contribution Margin By Level of Care
VITAS Analysis of Direct Gross Profit Contribution Margin By Level of Care 2003 through 2024 (in millions) 29 Chemed Corporation
Slide 30: VITAS – Summary of Operations 2004-2012
VITAS – Summary of Operations (a) For The Years Ended December 31, 2004 through 2012 (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) (9) 2004 2005 2006 2007 2008 2009 2010 2011 2012 (1) Service Revenues and Sales $ 531,136 $ 618,613 $ 699,092 $ 755,426 $ 808,445 $ 854,343 $ 925,81
Slide 31: VITAS – Summary of Operations 2013-2024
VITAS – Summary of Operations For The Years Ended December 31, 2013 through 2024 (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) Average Annual Inc./(Dec.) 2013 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2004-2024 (1) Service Revenues and Sales $ 1,045,11
Slide 32: VITAS – Operating Results
(a) VITAS – Operating Results (in thousands, except percentages) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) Average Annual 2003 (b) 2004 (b) 2006 2008 2010 2012 2014 2016 2018 2019 2020 2021 2022 2023 2024 Inc./(Dec.) (1) Net Service Revenue $ 441,017 $ 531,136 $ 699,092
Slide 33: VITAS – Results from Continuing Operations
VITAS – Results from Continuing Operations ($000) (1) (2) (3) Full-Year Results Fav/(Unfav) 2023 2024 % Growth (1) Service Revenues Before Medicare Cap $ 1,323,065 $ 1,539,392 16.4% (2) Medicare Cap (8,000) (8,414) (5.2%) (3) Net Service Revenues and Sales $ 1,315,065 $ 1,530,978 16.4% (4) Adj. Net
Slide 34: Future of VITAS
Future of VITAS Short-term ◆Continue organic growth ◆Acquisitions Fragmented industry Dominated by “Mom & Pop” not-for-profits Bottom 50% of provider numbers have an estimated average operating margin in hospice of 4% - 8%* ◆Access to reasonably priced capital critical to expansion Long-term ◆
Slide 35: VITAS – Operating Metrics ($000)
VITAS – Operating Metrics ($000) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) 2020 2021 2022 2023 2024 Operating Metrics Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 (1) Average Daily Census (ADC) 19,215 19,195 19,045 18,718 18,050 17,995
Slide 36: Appendix
Appendix
Slide 37: EPS and Stock Price History
(1) (2) EPS and Stock Price History Chemed has delivered strong and consistent EPS to Diluted EPS stockholders since 2003, 20.4% 21-year CAGR Adj. Stock (GAAP) Price $20.00 $650 $19.00 $625 $18.00 $600 $575 $17.00 $550 $16.00 $525 $15.00 $500 $475 $14.00 $450 $13.00 $425 $12.00 $400 $375 $11.00 $350
Slide 38: Medicare Hospice Spending (in billions)
Medicare Hospice Spending (in billions) $23.1 $23.7 $24.0 $22.4 $20.9 $22.0 $19.2 $20.0 $17.9 $16.8 $18.0 $15.9 $15.1 $15.1 $15.1 $16.0 $13.8 $12.9 $14.0 $12.0 $12.0 $10.0 $8.0 $6.0 $4.0 $2.4 8% 7% 9% 0% 0% 5% 6% 7% 7% 9% 7% 3% 3% $2.0 $0.0 1999 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019
Slide 39: Growth in Hospice Programs
Growth in Hospice Programs Source: MedPAC Report to the Congress – 2011 through 2024 39 Chemed Corporation
Slide 40: Reconciliation of Adjusted EBITDA 2004-2024
CHEMED CORPORATION RECONCILIATION OF ADJUSTED EBITDA FOR THE YEARS ENDED DECEMBER 31, 2004 THROUGH 2024 (IN THOUSANDS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 2004 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Reconciliation of Adjusted EBI
Slide 41: Reconciliation of Adjusted Net Income 2004-2024
CHEMED CORPORATION RECONCILIATION OF ADJUSTED NET INCOME FOR THE YEARS ENDED DECEMBER 31, 2004 THROUGH 2024 (IN THOUSANDS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (1) 2004 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 Reconciliation of Adjusted
Slide 42: Roto-Rooter Group Reconciliation of Adjusted EBITDA and Net Income
ROTO-ROOTER GROUP RECONCILIATION OF ADJUSTED EBITDA and ADJUSTED NET INCOME FOR THE YEARS ENDED DECEMBER 31, 2004 THROUGH 2024 (IN THOUSANDS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 20
Slide 43: Healthcare Group Reconciliation of Adjusted EBITDA and Net Income
VITAS HEALTHCARE GROUP RECONCILIATION OF ADJUSTED EBITDA and ADJUSTED NET INCOME FOR THE YEARS ENDED DECEMBER 31, 2004 THROUGH 2024 (a) (IN THOUSANDS) (1) (2) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) 2004 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 202
Slide 44: Chemed Reconciliation of Adjusted EBITDA and Net Income 2023-2024
CHEMED CORPORATION RECONCILIATION OF ADJUSTED EBITDA AND ADJUSTED NET INCOME FOR THE YEARS ENDED 2023 AND 2024 (IN THOUSANDS) 2023 2024 Reconciliation of Adjusted EBITDA (1) Net income $ 272,509 $ 301,999 (2) Interest expense 3,108 1,780 (3) Income taxes 77,858 97,466 (4) Depreciation 50,802 52,864
Slide 45: Roto-Rooter Reconciliation of Adjusted EBIT and EBITDA
ROTO-ROOTER GROUP RECONCILIATION OF ADJUSTED EBIT AND ADJUSTED EBITDA FOR THE YEARS ENDED 2023 AND 2024 (IN THOUSANDS) 2023 2024 Reconciliation of Adjusted EBIT and EBITDA (1) Net income $ 188,241 $ 160,046 (2) Interest expense 442 431 (3) Income taxes 50,125 48,510 (4) EBIT 238,808 208,987 Add/(ded
Slide 46: Healthcare Group Reconciliation of Adjusted EBITDA
VITAS HEALTHCARE GROUP RECONCILIATION OF ADJUSTED EBITDA FOR THE YEARS ENDED 2023 AND 2024 (IN THOUSANDS) Reconciliation of Adjusted EBITDA 2023 2024 (1) Net income $ 158,509 $ 216,819 (2) Interest expense 180 171 (3) Income taxes 46,115 67,414 (4) Depreciation 19,959 20,362 (5) Amortization 104 105
Slide 47: Chemed Corporation Contact Information
255 East 5th Street Suite 2600 Kevin J. McNamara Cincinnati, OH 45202 President and CEO kevin.mcnamara@chemed.com (513) 762-6690 Phone Michael D. Witzeman VP, CFO and Controller (513) 762-6919 Fax michael.witzeman@chemed.com www.chemed.com